ObesitySCHIZOBARNCT06043206
Bariatric Surgery in Patients With Schizophrenia
An observational study of Obesity and Schizophrenia, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
Trial summary
It is known that schizophrenia is associated with obesity in a significant number of patients and it implies a poor prognostic factor, with weight loss being important in this population. However, data about the prognosis of weight loss surgery in subjects with schizophrenia is scant. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Obesity, Schizophrenia
- What is being tested?
- Bariatric Surgery
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteSpain
- Study dates
- 1 Oct 2022to 30 Jun 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: subjects undergoing bariatric surgery
Who may be able to join
- Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
- Patient with schizophrenia or schizoaffective disorder.
- Exclusion) Subjects who do not meet any of the two inclusion criteria
- Controls: in a 4:1 ratio with cases
- Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
- Absence of psychiatric pathology
- Paired with the cases by age, sex, BMI before surgery and type of surgery.
- Exclusion) Subjects who do not meet any of the two inclusion criteria
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
It is known that schizophrenia is associated with obesity in a significant number of patients and it implies a poor prognostic factor, with weight loss being important in this population. However, data about the prognosis of weight loss surgery in subjects with schizophrenia is scant.
Hypothesis: Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia Main goal: To study the evolution after bariatric surgery in patients with obesity and schizophrenia Design: Multicenter retrospective case control study. Disease under study: Schizophrenia and Obesity Methodology: Retrospective observational study Study population and total number of subjects Cases: Patients with schizophrenia and obesity undergoing bariatric surgery. (number: all cases collected within the GOSEEN group).
Read more
Controls: Patients without psychiatric pathology matched by age, sex, body mass index and type of surgery and in a 4:1 ratio to cases.
Calendar. Expected duration of the study. 12 months ethical considerations Informed consent will be obtained from patients who are currently being followed up at the reference centers.
Read the detailed description
THEORETICAL FRAMEWORK. PROBLEM STATEMENT:
Background Obesity affects approximately 45-55% of patients with schizophrenia (1). Weight gain in these patients may be due to different factors such as the use of antipsychotic drugs with an unfavorable metabolic profile, the coexistence of sleep disorders or negative cognitive symptoms that often translate into a more sedentary lifestyle and alterations in eating behavior, among others (2). The coexistence of obesity and its comorbidities in this group of patients significantly worsens both their physical and mental health (3). In fact, cardiovascular disease is one of the main causes of mortality in patients with schizophrenia (4).
Lifestyle interventions, while they may be effective in people with schizophrenia (5), often fall short of achieving weight goals. At present, obesity surgery represents the most effective treatment in terms of weight loss and resolution of comorbidities, being indicated in cases of patients with a body mass index (BMI) > 35 kg/m2 with comorbidities or BMI > 40 Kg/m2 with/without comorbidities. However, the access of patients with schizophrenia to bariatric surgery techniques is usually limited by different factors such as fear of a possible worsening of the underlying disease, or a lower weight loss in this population, among others. In addition, clinical practice guidelines recommend that all patients with psychiatric pathologies be evaluated in a regulated manner prior to surgery (6), although the content of this evaluation and the criteria for declining or accepting surgery are not clear. Although the course of schizophrenia is variable and its symptoms may be stable without being a clear contraindication for bariatric surgery, in actual practice, a considerable number of professionals contraindicate bariatric surgery in the presence of a psychotic disorder (7).
For these reasons, data on the efficacy of bariatric surgery in patients with schizophrenia are scarce and limited to very small case series with short-term follow-up (2,8,9). Our objective is therefore to carry out a multicenter retrospective study that allows us to study the long-term evolution after bariatric surgery in a large series of patients, focusing not only on weight evolution but also on the long-term evolution of psychiatric pathology.
Justification It is necessary to have information about the prognosis of subjects with severe obesity and schizophrenia who undergo bariatric surgery. This knowledge will make it possible to establish clear guidelines for action in these cases.
Research questions What is the long-term outcome after bariatric surgery in subjects with schizophrenia? Hypothesis Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia
GOALS:
Main goal:
To study the short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery in Spain and compare it with the evolution of patients without psychiatric disorder.
Secondary objectives:
- Determine the casuistry of patients, with special interest in the characteristics of the underlying psychiatric pathology (years of evolution, clinical stability criteria, pharmacological treatment...).
- To Analyze the evolution of obesity comorbidities.
- To Analyze the evolution of psychiatric pathology after bariatric surgery: (decompensation, drug treatment...)
- To analyze the frequency of early (<30 days post-surgery) or late (>30 days post-surgery) post-surgical complications.
METHODS:
Study design Retrospective case-control study.
Expected sample size All cases detected in Spanish territory The minimum number of cases expected will be 10 patients based on the low casuistry of the problem. The number of patients in the control group will be x4 that in the study group.
Methodology. Information sources The study population will be identified in each center in the usual specialty consultations or by searching the databases of each center. Review of medical records in search of the specified variables (retrospective observational study).
Data Management and Analysis The coordinating researcher (Dra Inka Miñambres Donaire) will be responsible for the creation of the database and its exploitation. The database will be created in Excell format and the SPSS program will be used for statistical analysis. The statistics will be mainly descriptive. For cases in which it is decided to compare groups, normality tests will be used to establish the behavior of the variables and parametric/non-parametric tests will be used as appropriate.
Data collection The researcher will guarantee the accuracy and integrity of the data, as well as all the reports that are required. The data included in the Data Collection Notebook (CRD), which are derived from source documents, will be consistent with those documents or otherwise the discrepancies will be justified.
The researcher will keep the study documents until at least 5 years after completion.
At the request of the monitor, auditor, ethics committee or health authority, the researcher will have available all the files related to the study, allowing direct access to the data or source documents for monitoring, auditing, review by the ethics committee, as well as the inspection of the trial by the competent authorities.
Limitations of the design, the source of information and the methods of analysis
The main limitation of the study is its retrospective nature. However, the study design is adequate given the low frequency of the pathology.
Data confidentiality Regarding the confidentiality of the study data, the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights and the General Regulation (EU) on Data Protection will be followed. 2016/679.
Interference with physician's prescribing habits As it is a retrospective study, there will be no interference with the prescribing habits of the doctor.
- Conditions
- Obesity, Schizophrenia
- Being tested
- Bariatric Surgery
- Keywords
- Bariatric Surgery, Hospital care, Observational study, weight loss, evolution
- Medical subject headings
- Obesity, Schizophrenia, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bariatric SurgeryProcedure or surgery
Bariatric Surgery
| Study group | Role | What they receive |
|---|---|---|
| Cases Obesity and schizophrenia | Patients with schizophrenia and obesity undergoing bariatric surgery Receives: Procedure: Bariatric Surgery | |
| Controls | Patients without psychiatric pathology matched by age, sex, BMI and type of surgery and in a 4:1 ratio to cases. Receives: Procedure: Bariatric Surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight loss
short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery
Measured: 12 months and 5 years after the surgery
Secondary outcomes (4)
Clincial Caracteristics description
casuistry of patients, with special interest in the characteristics of the underlying psychiatric pathology (years of evolution, clinical stability criteria, pharmacological treatment...)
Measured: inclusion, day 1
Comorbidity progression
Analyze the evolution of obesity comorbidities: presence of type 2 diabetes, hypertension, OSAS and dyslipidemia. Remission of co morbidities was defined as cessation of medication for hypertension or hyperlipidemia with normal blood pressure and lipid levels, cessation for continuous positive pressure ventilation for sleep apnea, and normalization of HbA1C (<6.5) with no medications for diabetes.
Measured: 12 months and 5 years after the surgery
Psychiatric pathology progression
Analyze the evolution of psychiatric treatment: Psychiatric medication burden will be calculated by generating a continuous variable using a previous validated formula (Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents Joseph T. Hanlon, J Am Geriatr Soc. 2017 June ; 65(6): 1183-1189. doi:10.1111/jgs.14759).
Measured: 30 days post surgery and 5 years after the surgery
post-surgical complications
To analyze the frequency of early or late post-surgical complications
Measured: up to 30 days post-surgery) or late post-surgical complications (through study completion, up to five years post-surgery)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2023
- Study start1 Oct 2022
- Primary completion30 Jun 2023
- Study completion30 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital del Mar, Hospital Universitario Reina Sofia de Cordoba, Parc Taulí Hospital Universitari, University Hospital A Coruña, Hospital General Universitario Gregorio Marañon, University of Navarrra Hospital (Clinica Universitaria), Hospital Clinic of Barcelona, León University Assistance Complex, Leon, Spain, Valle del Nalón Hospital, Asturias, Spain, Complejo Hospitalario Universitario de Vigo, Hospital Arnau de Vilanova, Hospital San Carlos, Madrid, Hospital Universitari de Bellvitge, Hospitales Universitarios Virgen del Rocío, Hospital Regional de Malaga, Germans Trias i Pujol Hospital, Hospital Universitario Virgen Macarena, Hospital Mutua de Terrassa, Hospital Son Llatzer, University Hospital of Girona Dr. Josep Trueta, University Hospital of the Canary Islands, Tenerife, Spain, Hospital Virgen de la Luz, Hospital Universitario Virgen de la Victoria, Hospital de Viladecans, Hospital Universitario Doctor Peset, Hospital Universitari Sant Joan de Reus, General Hospital, Vic, Spain
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06043206
- Sponsor's protocol ID
- IIBSP-BAR-2022-30
- Acronym
- SCHIZOBAR
- Status last verified
- Sep 2023
- First submitted
- 3 Sep 2023
- Last updated
- 21 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: individual participant data can not be available due to the data protection law restrictions, however, anonymized data could be shared on demand
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bariatric Surgery in Patients With Schizophrenia
- ClinicalTrials.gov ID
- NCT06043206
- Acronym / sponsor ID
- SCHIZOBAR / IIBSP-BAR-2022-30
- Conditions
- Obesity, Schizophrenia
- Keywords
- Bariatric Surgery, Hospital care, Observational study, weight loss, evolution
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauUniversity, hospital or other
- Collaborators
- Hospital del Mar, Hospital Universitario Reina Sofia de Cordoba, Parc Taulí Hospital Universitari, University Hospital A Coruña, Hospital General Universitario Gregorio Marañon, University of Navarrra Hospital (Clinica Universitaria), Hospital Clinic of Barcelona, León University Assistance Complex, Leon, Spain, Valle del Nalón Hospital, Asturias, Spain, Complejo Hospitalario Universitario de Vigo, Hospital Arnau de Vilanova, Hospital San Carlos, Madrid, Hospital Universitari de Bellvitge, Hospitales Universitarios Virgen del Rocío, Hospital Regional de Malaga, Germans Trias i Pujol Hospital, Hospital Universitario Virgen Macarena, Hospital Mutua de Terrassa, Hospital Son Llatzer, University Hospital of Girona Dr. Josep Trueta, University Hospital of the Canary Islands, Tenerife, Spain, Hospital Virgen de la Luz, Hospital Universitario Virgen de la Victoria, Hospital de Viladecans, Hospital Universitario Doctor Peset, Hospital Universitari Sant Joan de Reus, General Hospital, Vic, Spain
- Study start
- 1 Oct 2022 (actual)
- Primary completion
- 30 Jun 2023 (actual)
- Study completion
- 30 Jun 2023 (actual)
- First posted
- 21 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is known that schizophrenia is associated with obesity in a significant number of patients and it implies a poor prognostic factor, with weight loss being important in this population. However, data about the prognosis of weight loss surgery in subjects with schizophrenia is scant.
Hypothesis: Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia Main goal: To study the evolution after bariatric surgery in patients with obesity and schizophrenia Design: Multicenter retrospective case control study. Disease under study: Schizophrenia and Obesity Methodology: Retrospective observational study Study population and total number of subjects Cases: Patients with schizophrenia and obesity undergoing bariatric surgery. (number: all cases collected within the GOSEEN group).
Controls: Patients without psychiatric pathology matched by age, sex, body mass index and type of surgery and in a 4:1 ratio to cases.
Calendar. Expected duration of the study. 12 months ethical considerations Informed consent will be obtained from patients who are currently being followed up at the reference centers.
Detailed description
THEORETICAL FRAMEWORK. PROBLEM STATEMENT:
Background Obesity affects approximately 45-55% of patients with schizophrenia (1). Weight gain in these patients may be due to different factors such as the use of antipsychotic drugs with an unfavorable metabolic profile, the coexistence of sleep disorders or negative cognitive symptoms that often translate into a more sedentary lifestyle and alterations in eating behavior, among others (2). The coexistence of obesity and its comorbidities in this group of patients significantly worsens both their physical and mental health (3). In fact, cardiovascular disease is one of the main causes of mortality in patients with schizophrenia (4).
Lifestyle interventions, while they may be effective in people with schizophrenia (5), often fall short of achieving weight goals. At present, obesity surgery represents the most effective treatment in terms of weight loss and resolution of comorbidities, being indicated in cases of patients with a body mass index (BMI) > 35 kg/m2 with comorbidities or BMI > 40 Kg/m2 with/without comorbidities. However, the access of patients with schizophrenia to bariatric surgery techniques is usually limited by different factors such as fear of a possible worsening of the underlying disease, or a lower weight loss in this population, among others. In addition, clinical practice guidelines recommend that all patients with psychiatric pathologies be evaluated in a regulated manner prior to surgery (6), although the content of this evaluation and the criteria for declining or accepting surgery are not clear. Although the course of schizophrenia is variable and its symptoms may be stable without being a clear contraindication for bariatric surgery, in actual practice, a considerable number of professionals contraindicate bariatric surgery in the presence of a psychotic disorder (7).
For these reasons, data on the efficacy of bariatric surgery in patients with schizophrenia are scarce and limited to very small case series with short-term follow-up (2,8,9). Our objective is therefore to carry out a multicenter retrospective study that allows us to study the long-term evolution after bariatric surgery in a large series of patients, focusing not only on weight evolution but also on the long-term evolution of psychiatric pathology.
Justification It is necessary to have information about the prognosis of subjects with severe obesity and schizophrenia who undergo bariatric surgery. This knowledge will make it possible to establish clear guidelines for action in these cases.
Research questions What is the long-term outcome after bariatric surgery in subjects with schizophrenia? Hypothesis Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia
GOALS:
Main goal:
To study the short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery in Spain and compare it with the evolution of patients without psychiatric disorder.
Secondary objectives:
- Determine the casuistry of patients, with special interest in the characteristics of the underlying psychiatric pathology (years of evolution, clinical stability criteria, pharmacological treatment...).
- To Analyze the evolution of obesity comorbidities.
- To Analyze the evolution of psychiatric pathology after bariatric surgery: (decompensation, drug treatment...)
- To analyze the frequency of early (<30 days post-surgery) or late (>30 days post-surgery) post-surgical complications.
METHODS:
Study design Retrospective case-control study.
Expected sample size All cases detected in Spanish territory The minimum number of cases expected will be 10 patients based on the low casuistry of the problem. The number of patients in the control group will be x4 that in the study group.
Methodology. Information sources The study population will be identified in each center in the usual specialty consultations or by searching the databases of each center. Review of medical records in search of the specified variables (retrospective observational study).
Data Management and Analysis The coordinating researcher (Dra Inka Miñambres Donaire) will be responsible for the creation of the database and its exploitation. The database will be created in Excell format and the SPSS program will be used for statistical analysis. The statistics will be mainly descriptive. For cases in which it is decided to compare groups, normality tests will be used to establish the behavior of the variables and parametric/non-parametric tests will be used as appropriate.
Data collection The researcher will guarantee the accuracy and integrity of the data, as well as all the reports that are required. The data included in the Data Collection Notebook (CRD), which are derived from source documents, will be consistent with those documents or otherwise the discrepancies will be justified.
The researcher will keep the study documents until at least 5 years after completion.
At the request of the monitor, auditor, ethics committee or health authority, the researcher will have available all the files related to the study, allowing direct access to the data or source documents for monitoring, auditing, review by the ethics committee, as well as the inspection of the trial by the competent authorities.
Limitations of the design, the source of information and the methods of analysis
The main limitation of the study is its retrospective nature. However, the study design is adequate given the low frequency of the pathology.
Data confidentiality Regarding the confidentiality of the study data, the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights and the General Regulation (EU) on Data Protection will be followed. 2016/679.
Interference with physician's prescribing habits As it is a retrospective study, there will be no interference with the prescribing habits of the doctor.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases Obesity and schizophrenia | – | Procedure: Bariatric SurgeryPatients with schizophrenia and obesity undergoing bariatric surgery |
| Controls | – | Procedure: Bariatric SurgeryPatients without psychiatric pathology matched by age, sex, BMI and type of surgery and in a 4:1 ratio to cases. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- subjects undergoing bariatric surgery
Key inclusion criteria (8 listed)
- Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
- Patient with schizophrenia or schizoaffective disorder.
- Exclusion) Subjects who do not meet any of the two inclusion criteria
- Controls: in a 4:1 ratio with cases
- Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bariatric SurgeryBariatric Surgery | Procedure or surgery | Cases Obesity and schizophrenia, Controls |
Primary outcome
Weight loss
Time frame: 12 months and 5 years after the surgery
short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery
4 secondary outcomes
Clincial Caracteristics description
Time frame: inclusion, day 1
Comorbidity progression
Time frame: 12 months and 5 years after the surgery
Psychiatric pathology progression
Time frame: 30 days post surgery and 5 years after the surgery
post-surgical complications
Time frame: up to 30 days post-surgery) or late post-surgical complications (through study completion, up to five years post-surgery)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
- Individual participant dataSharing planned: No. individual participant data can not be available due to the data protection law restrictions, however, anonymized data could be shared on demand
Related trials for Obesity
Active, not recruitingPhase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
Electric Stimulation Therapy, Obesity
Not yet recruiting
High-Flow Nasal Oxygen-Assisted Deep Extubation Versus Awake Extubation in Morbidly Obese Patients
Deep Tracheal Extubation
Active, not recruiting
Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function
Obesity, Weight Loss
Not yet recruitingPhase 2
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Insulin Resistance, Obesity
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and Schizophrenia, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight loss (time frame: 12 months and 5 years after the surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.